| DODGX | PEIYX | DODGX / PEIYX | |
| Total Expense Ratio | 0.51 | 0.60 | 85% |
| Annual Report Gross Expense Ratio | 0.51 | 0.60 | 85% |
| Fund Existence | 62 years | 28 years | - |
| Gain YTD | 6.823 | 14.787 | 46% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 123B | 56.1B | 219% |
| Annual Yield % from dividends | 1.04 | 1.06 | 98% |
| Returns for 1 year | 7.50 | 17.09 | 44% |
| Returns for 3 years | 109.28 | 54.23 | 202% |
| Returns for 5 years | 159.69 | 53.87 | 296% |
| Returns for 10 years | 466.90 | 149.78 | 312% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SSPIX | 113.65 | 0.19 | +0.17% |
| SEI S&P 500 Index F (SIMT) | |||
| CGVHX | 30.97 | 0.01 | +0.03% |
| American Funds Global Insight 529-F-3 | |||
| CCSMX | 20.99 | -0.06 | -0.29% |
| Conestoga SMid Cap Investors | |||
| BMSTX | 17.20 | -0.09 | -0.52% |
| MFS Blended Research Mid Cap Eq R3 | |||
| PHPIX | 43.30 | -0.90 | -2.04% |
| ProFunds Pharmaceuticals UltraSector Inv | |||